AstraZeneca PLC (NASDAQ:AZN) Shares Sold by Princeton Global Asset Management LLC

Princeton Global Asset Management LLC decreased its position in AstraZeneca PLC (NASDAQ:AZN) by 3.9% in the 3rd quarter, HoldingsChannel reports. The firm owned 3,793 shares of the company’s stock after selling 155 shares during the period. Princeton Global Asset Management LLC’s holdings in AstraZeneca were worth $295,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD lifted its stake in shares of AstraZeneca by 17.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 61,271,974 shares of the company’s stock valued at $4,151,177,000 after buying an additional 9,002,450 shares during the period. Capital World Investors lifted its stake in shares of AstraZeneca by 0.3% during the 1st quarter. Capital World Investors now owns 9,365,676 shares of the company’s stock worth $634,525,000 after purchasing an additional 29,497 shares during the period. Envestnet Asset Management Inc. boosted its holdings in shares of AstraZeneca by 16.7% during the second quarter. Envestnet Asset Management Inc. now owns 3,417,933 shares of the company’s stock worth $266,565,000 after purchasing an additional 488,644 shares during the last quarter. Clearbridge Investments LLC grew its position in shares of AstraZeneca by 5.8% in the second quarter. Clearbridge Investments LLC now owns 3,403,748 shares of the company’s stock valued at $265,458,000 after purchasing an additional 186,010 shares during the period. Finally, Fayez Sarofim & Co increased its stake in AstraZeneca by 4.7% in the first quarter. Fayez Sarofim & Co now owns 2,990,234 shares of the company’s stock valued at $202,588,000 after purchasing an additional 134,784 shares during the last quarter. 20.35% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on AZN shares. Erste Group Bank raised shares of AstraZeneca from a “hold” rating to a “buy” rating in a research note on Wednesday, September 11th. Deutsche Bank Aktiengesellschaft lowered shares of AstraZeneca from a “hold” rating to a “sell” rating in a research report on Friday, September 13th. Finally, TD Cowen lifted their price target on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $89.75.

AstraZeneca Price Performance

AstraZeneca stock opened at $71.42 on Monday. The firm has a fifty day moving average of $79.17 and a 200-day moving average of $78.75. AstraZeneca PLC has a 52-week low of $60.47 and a 52-week high of $87.68. The company has a quick ratio of 0.69, a current ratio of 0.89 and a debt-to-equity ratio of 0.69. The firm has a market capitalization of $221.44 billion, a P/E ratio of 34.50, a PEG ratio of 1.32 and a beta of 0.47.

AstraZeneca Company Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.